Last reviewed · How we verify

NCT05391906

Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in Multiple Sclerosis

Active, enrolled NA Last updated 12 March 2025
What this trial tests

NA trial testing Diffusion-weighted magnetic resonance imaging in Multiple Sclerosis in 50 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
30 January 2023
Primary endpoint
20 December 2026
30 December 2026

Quick facts

Lead sponsorChinese University of Hong Kong
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment50
Start date30 January 2023
Primary completion20 December 2026
Estimated completion30 December 2026
Sites1 location across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intravoxel incoherent motion (IVIM) is technique based on diffusion-weighted imaging (DWI). In this study, the investigators evaluate the use of IVIM in patients with Multiple Sclerosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05391906.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing